A Phase I Trial of p28 (Cell Penetrating Peptide) in the Treatment of Refractory Solid Tumors
The purpose of this study is to evaluate the safety of an experimental drug (p28) as a treatment for certain advanced cancers which express a protein called p53 and which have not responded to prior treatment.
100 Clinical Results associated with CDG Therapeutics, Inc.
0 Patents (Medical) associated with CDG Therapeutics, Inc.
100 Deals associated with CDG Therapeutics, Inc.
100 Translational Medicine associated with CDG Therapeutics, Inc.